These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27841042)

  • 1. Treatments and compositions targeting α-synuclein: a patent review (2010-2016).
    Jęśko H; Lenkiewicz AM; Adamczyk A
    Expert Opin Ther Pat; 2017 Apr; 27(4):427-438. PubMed ID: 27841042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
    Prigione A; Piazza F; Brighina L; Begni B; Galbussera A; Difrancesco JC; Andreoni S; Piolti R; Ferrarese C
    Neurosci Lett; 2010 Jun; 477(1):6-10. PubMed ID: 20399833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.
    Joubert J
    Expert Opin Ther Pat; 2018 Dec; 28(12):939-945. PubMed ID: 30359535
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
    Lingor P; Carboni E; Koch JC
    J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.
    Moussaud S; Malany S; Mehta A; Vasile S; Smith LH; McLean PJ
    Expert Opin Ther Targets; 2015 May; 19(5):589-603. PubMed ID: 25785645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies against the C-terminus of α-synuclein modulate its fibrillation.
    Sahin C; Lorenzen N; Lemminger L; Christiansen G; Møller IM; Vesterager LB; Pedersen LØ; Fog K; Kallunki P; Otzen DE
    Biophys Chem; 2017 Jan; 220():34-41. PubMed ID: 27863716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration.
    Wilkaniec A; Strosznajder JB; Adamczyk A
    Neurochem Int; 2013 Apr; 62(5):776-83. PubMed ID: 23416621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of α-synuclein for the treatment of Parkinson's disease: a patent landscape.
    Joubert J
    Pharm Pat Anal; 2020 May; 9(3):63-65. PubMed ID: 32602809
    [No Abstract]   [Full Text] [Related]  

  • 12. Zeroing in on neurodegenerative α-synuclein.
    Kingwell K
    Nat Rev Drug Discov; 2017 May; 16(6):371-373. PubMed ID: 28559555
    [No Abstract]   [Full Text] [Related]  

  • 13. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.
    Serafino A; Sferrazza G; Colini Baldeschi A; Nicotera G; Andreola F; Pittaluga E; Pierimarchi P
    Expert Opin Drug Discov; 2017 Feb; 12(2):169-186. PubMed ID: 27960558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alpha-synuclein in Parkinson's disease].
    Oczkowska A; Kozubski W; Dorszewska J
    Przegl Lek; 2014; 71(1):26-32. PubMed ID: 24712265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein propagation: New insights from animal models.
    Dehay B; Vila M; Bezard E; Brundin P; Kordower JH
    Mov Disord; 2016 Feb; 31(2):161-8. PubMed ID: 26347034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
    Sardi SP; Cheng SH; Shihabuddin LS
    Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins.
    Cox D; Carver JA; Ecroyd H
    Biochim Biophys Acta; 2014 Sep; 1842(9):1830-43. PubMed ID: 24973551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein aggregation and modulating factors.
    Paleologou KE; El-Agnaf OM
    Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.